Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $49
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $28 to $49.
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $28 to $49.